Cargando…
Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls
Trop-2 is an ideal candidate for targeted therapeutics because it is a transmembrane protein with an extracellular domain overexpressed in a wide variety of tumors, and is upregulated in normal cells. Consequently, several Trop-2-targeted drugs have recently been developed for clinical use, such as...
Autores principales: | Bravaccini, Sara, Maltoni, Roberta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620404/ https://www.ncbi.nlm.nih.gov/pubmed/34834563 http://dx.doi.org/10.3390/jpm11111211 |
Ejemplares similares
-
Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer
por: Maltoni, Roberta, et al.
Publicado: (2022) -
CD68, CD163, and matrix metalloproteinase 9 (MMP-9) in breast tumor microenvironment to predict breast cancer survival: are they enough?
por: Bravaccini, Sara, et al.
Publicado: (2019) -
Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer
por: Cardillo, Thomas M., et al.
Publicado: (2020) -
Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer
por: Jeon, Yeonjin, et al.
Publicado: (2022) -
Correlation of TROP-2 expression with clinical–pathological characteristics and outcome in triple-negative breast cancer
por: Izci, Hava, et al.
Publicado: (2022)